Alumis Inc.
Live Market Data
About Company
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Industry Segment
Price Chart
Technical Analysis
Technical Outlook
Valuation Check
Research Reports
Daily – Vickers Top Insider Picks for 03/26/2026
Daily – Vickers Top Insider Picks for 03/25/2026
Quarterly Results
| Particulars | Sept 25 | Dec 24 | Sept 24 | Jan 70 | Jan 70 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0.21 | 0 | 0 | 0.27 | 1.74 |
| Net Income (Cr) | -11.08 | -9.48 | -9.31 | 5.93 | -9.9 |
| EPS (₹) | -1.06 | 0 | -1.73 | 0.57 | -1.82 |
Annual Profit & Loss
| Particulars | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 |
| Operating Exp (Cr) | 30.08 | 15.82 | 11.38 |
| Net Income (Cr) | -29.42 | -15.5 | -11.19 |
| EPS (₹) | -10.38 | -2.99 | -2.91 |
Balance Sheet
| Particulars | Sept 25 | Dec 24 | Sept 24 | Jan 70 | Jan 70 |
|---|---|---|---|---|---|
| Total Assets (Cr) | 48.8 | 34.1 | 41.26 | 61.09 | 26.13 |
| Total Liabilities (Cr) | 10.32 | 8.09 | 6.42 | 12.56 | 9.3 |
| Total Equity (Cr) | 38.48 | 26.01 | 34.84 | 48.53 | 16.83 |
Key Ratios Fundamentals
Valuation
Profitability
Liquidity & Debt
Price Statistics
Pattern Unavailable
Detailed shareholding breakdown is not currently provided by the exchange.